Cell-based immunotherapy against gliomas: from bench to bedside

Area of Science:

• Neuro-oncology
• Immunology
• Cancer Therapy

Background:

• Glioblastoma (GBM) is the most malignant glioma, accounting for 51% of all gliomas.
• Current standard-of-care (surgery, radiation, chemotherapy) offers limited efficacy, with a median survival of 18-21 months.
• Poor outcomes highlight the need for novel therapeutic approaches.

Purpose of the Study:

• To review recent advances in cellular immunotherapy for gliomas.
• To discuss active, passive, and vaccine-based immunotherapeutic strategies.
• To bridge the gap between preclinical research and clinical application for brain tumors.

Main Methods:

• Literature review of immunotherapy strategies for gliomas.
• Analysis of active immunotherapy (e.g., CAR T-cells).
• Evaluation of passive immunotherapy (e.g., antibodies) and vaccine-based approaches.

Main Results:

• Immunotherapy demonstrates potential in preclinical and clinical settings for gliomas.
• Various strategies are being investigated to overcome challenges in brain tumor treatment.
• Advances span different immunotherapy modalities, offering diverse therapeutic avenues.

Conclusions:

• Cellular immunotherapy represents a promising frontier for treating malignant gliomas.
• Continued research and clinical trials are crucial for optimizing these novel treatments.
• Immunotherapy holds potential to improve survival rates for glioblastoma patients.